Related Experiment Video

Updated: Mar 13, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.6K

Current strategies to create tailored and risk-adapted therapies for CLL patients

Paula Cramer1, Barbara Eichhorst1, Hans Christian Reinhardt2

  • 1Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University Hospital, Cologne, Germany; German CLL Study Group, University Hospital Cologne, Cologne, Germany.

Best Practice & Research. Clinical Haematology
|October 16, 2016
PubMed

Insights

Researchers are exploring optimal, non-toxic combinations of novel agents for chronic lymphocytic leukemia (CLL) therapy. The German CLL Study Group

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Chronic lymphocytic leukemia (CLL) therapy is evolving with new drug development.
  • Identifying non-toxic combination therapies is a key objective in CLL treatment.

Purpose of the Study:

  • To update on novel agents for CLL therapy.
  • To detail the German CLL Study Group's strategy for combining novel agents.
  • To present initial findings from the BXX series of Phase II combination trials.

Main Methods:

  • Review of novel drugs for CLL.
  • Description of combination strategies employed by the German CLL Study Group.
  • Analysis of early results from Phase II trials (BXX series).

Main Results:

  • The article highlights promising novel agents for CLL.
  • The German CLL Study Group's combination strategy is detailed.
  • First results from the BXX series trials are presented, involving agents like venetoclax and ibrutinib.

Conclusions:

  • Optimal non-toxic combinations are crucial for advancing CLL therapy.
  • The described combination strategies and early trial results offer insights into future treatment approaches.
  • Further investigation into these novel combinations is warranted.
Keywords:
CLLIbrutinibIdelalisib (CAL-101)MRDMaintenanceObinutuzumab (GA101)OfatumumabVenetoclax (ABT-199)

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.1K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.2K